• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基层医疗诊所中药物辅助治疗的优缺点

The Advantages and Disadvantages of Medication-Assisted Treatment in Primary Care Offices.

作者信息

Padgett Tonja M

机构信息

Tonja M. Padgett, RN, DNP, ACNS-BC, Indiana University School of Nursing, Indianapolis.

出版信息

J Addict Nurs. 2019 Oct/Dec;30(4):238-241. doi: 10.1097/JAN.0000000000000305.

DOI:10.1097/JAN.0000000000000305
PMID:31800513
Abstract

Substance use disorder (SUD), more specifically opioid use disorder, is a national epidemic. Although there is an emphasis on treatment and increasing treatment locations, there continues to be a gap between the number of people with SUD and the number of treatment centers. To help narrow this gap, some primary care clinicians started providing medication-assisted treatment (MAT) on an outpatient basis in their offices. This option enables clinicians to provide treatment in their own communities, which increases access to treatment and decreases costs. It also enables the clinician and the person with SUD/opioid use disorder to build a relationship, which many clinicians believe is the foundation of successful treatment. The clinician, whether a doctor, a physician assistant, or an advanced practice nurse, has to obtain a Drug Addiction Treatment Act 2000 waiver to provide MAT beyond naltrexone, which has a required educational program and includes a limitation on the number of clients. Conversely, a possible drawback to this type of treatment is the potential for the disruption of continuity of care with regard to psychotherapy treatment. Federal law mandates that therapy is available and provided to people receiving MAT. The clinician may not be able to provide this service and would need to refer the person with SUD for psychotherapy treatment. It may be clinically significant for a type of follow-up communication to be implemented so that the clinician and the therapy provider can maximize SUD treatment success.

摘要

物质使用障碍(SUD),更具体地说是阿片类物质使用障碍,是一种全国性的流行病。尽管目前重点在于治疗并增加治疗场所,但患有物质使用障碍的人数与治疗中心的数量之间仍存在差距。为了帮助缩小这一差距,一些初级保健临床医生开始在其办公室门诊提供药物辅助治疗(MAT)。这种选择使临床医生能够在自己的社区提供治疗,从而增加了治疗的可及性并降低了成本。这也使临床医生与患有物质使用障碍/阿片类物质使用障碍的人建立关系,许多临床医生认为这是成功治疗的基础。临床医生,无论是医生、医师助理还是高级执业护士,若要提供除纳曲酮之外的药物辅助治疗,都必须获得2000年《药物成瘾治疗法》豁免,这需要参加一个必修教育课程,且对客户数量有限制。相反,这种治疗方式的一个可能缺点是在心理治疗方面存在护理连续性中断的可能性。联邦法律规定要为接受药物辅助治疗的人提供并给予治疗。临床医生可能无法提供这项服务,需要将患有物质使用障碍的人转介接受心理治疗。实施一种后续沟通方式可能具有临床意义,以便临床医生和治疗提供者能够最大限度地提高物质使用障碍治疗的成功率。

相似文献

1
The Advantages and Disadvantages of Medication-Assisted Treatment in Primary Care Offices.基层医疗诊所中药物辅助治疗的优缺点
J Addict Nurs. 2019 Oct/Dec;30(4):238-241. doi: 10.1097/JAN.0000000000000305.
2
The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015).洛杉矶县促进持续使用长效纳曲酮(XR-NTX)的中心和供应商网络(2010-2015 年)。
J Subst Abuse Treat. 2018 Feb;85:78-83. doi: 10.1016/j.jsat.2017.02.011. Epub 2017 Mar 11.
3
Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.基于初级保健的阿片类物质使用障碍治疗模式:一项范围综述
Ann Intern Med. 2017 Feb 21;166(4):268-278. doi: 10.7326/M16-2149. Epub 2016 Dec 6.
4
Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.最近获准开具丁丙诺啡用于治疗阿片类药物使用障碍的临床医生的特征和处方实践。
Addiction. 2019 Mar;114(3):471-482. doi: 10.1111/add.14436. Epub 2018 Oct 15.
5
Medication-assisted treatment for opioid use disorder.阿片类物质使用障碍的药物辅助治疗。
Nurse Pract. 2019 Mar;44(3):10-12. doi: 10.1097/01.NPR.0000550252.04526.79.
6
Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.基于 12 步治疗中心的阿片类药物使用障碍药物辅助治疗:可行性和初步结果。
J Subst Abuse Treat. 2019 Sep;104:51-63. doi: 10.1016/j.jsat.2019.06.009. Epub 2019 Jun 12.
7
The case for a medication first approach to the treatment of opioid use disorder.采用药物优先治疗阿片类药物使用障碍。
Am J Drug Alcohol Abuse. 2019;45(4):333-340. doi: 10.1080/00952990.2019.1605372. Epub 2019 May 14.
8
Cost and utilization outcomes of opioid-dependence treatments.阿片类药物依赖治疗的成本和利用结果。
Am J Manag Care. 2011 Jun;17 Suppl 8:S235-48.
9
Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.药物治疗在物质使用治疗设施中的阿片类药物使用障碍。
Health Aff (Millwood). 2019 Jan;38(1):14-23. doi: 10.1377/hlthaff.2018.05162.
10
Extended-release naltrexone for opioid use disorder started during or following incarceration.在监禁期间或之后开始使用纳曲酮长效制剂治疗阿片类药物使用障碍。
J Subst Abuse Treat. 2018 Feb;85:97-100. doi: 10.1016/j.jsat.2017.04.002. Epub 2017 Apr 6.

引用本文的文献

1
Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone.丁丙诺啡/纳洛酮供应与管理的医师-药师协作实践模式的开发与实施。
Ment Health Clin. 2021 Jan 8;11(1):35-39. doi: 10.9740/mhc.2021.01.035. eCollection 2021 Jan.